Olivier Soula and Mathieu-William Gilbert – Presentation Investir Day November 2025 (FR)
11/27/2025 ADOCIA – Investir Day – Nov. 2025 (FR) Icon check
Interview Olivier Soula 鈥� Bourse et Valeurs 鈥� July 2025 (FR)
General Shareholder’s meeting – June 11, 2025 (FR)
11/27/2024 ADOCIA 鈥� Investir Day 鈥� Nov. 2024 (FR) Icon check
Olivier Soula 鈥� Bourse et Valeurs, Lyon Pole Bourse 2024 (FR)
Web Conference – BioChaperone Combo – July 2024 (FR)
Interview Olivier Soula 鈥� La France de Demain, Radio Classique – May 2024 (FR)
Olivier Soula – LSX World Congress – April 2024
05/03/2024 Investor Presentation – LSX World Congress – April 2024 Icon check
Interview Olivier Soula – Le Journal des Biotechs – March 2024 (FR)
BIO-Europe Spring 2024: Interview with J茅r茅my Benattar
Web-conference – 4th Quarter 2023 Financial Results (FR)
02/29/2024 Web-conference – Financial Results – 2023 Fourth Quarter (French) Icon check
01/10/2024 ADOCIA – Investor Presentation – Biotech Showcase/JPM24 – January 2024 Icon check
Olivier Soula – Le Revenu TV – Dec. 2023 (FR)
Web conf茅rence – Diab猫te : un laboratoire pour le futur de la sant茅 – d茅c. 2023 (FR)
11/28/2023 ADOCIA – Investir Day – Nov 2023 (FR) Icon check
Olivier Soula – Investival Showcase
11/13/2023 ADOCIA – LSX Investival Presentation – Nov 2023 Icon check
J茅r茅my Benattar – Investisseur.TV (FR)
Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse (FR)
07/11/2023 EndoC-bH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion. Mol Metab. 2023 Jul 11;76:101772 Icon check
Webconference of July 6th, 2023
06/23/2023 AdoShell庐 Islets, a new biomaterial for allogenic islet encapsulation, shows 6 months insulin secretion in diabetic immunocompetent rats, Dr. Ouardane Jouannot, June 23, 2023, 83rd scientific Sessions, ADA 2023
2022 Annual Results
01/30/2023 ADOCIA – Letter to shareholders – January 2023 Icon check
01/12/2023 A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248.
Investors Webinar of Sept 20th, 2022
2022 AdoShell Islets Presentation
06/23/2022 ADOCIA – Letter to Shareholders – June 2022 Icon check
06/27/2021 ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Gr茅gory Meiffren, June 27, 2021, ADA virtual event.
06/02/2021 ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart聽 in type 1 diabetes, Dr. 聽Gr茅gory Meiffren, June 2, 2021, ATTD, Virtual event.
04/23/2021 ADO09, a co鈥恌ormulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970.
09/10/2020 ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr. 聽Gr茅gory Meiffren, September 10, 2020, Soci茅t茅 Francophone du Diab猫te, Virtual Event.
09/05/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/16/2020 ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience. Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/03/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
02/21/2020 鈥淏ioChaperone庐 Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects鈥� (EPO2 E-Poster Viewing), presented by Dr. Gr茅gory Meiffren, February 21, 2019, ATTD, Berlin (Germany) Icon check
06/10/2019 鈥淏ioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice鈥� (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA) Icon check
06/09/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D鈥�, Dr. Gr茅gory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
06/09/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D鈥�, Dr. Gr茅gory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
04/15/2019 Article : Gr茅gory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire M茅gret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum鈥怣枚rschel MD.
鈥淏etter glycemic control with BioChaperone庐 Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)鈥�
Diabetes Obes Metab., 2019;21(7):15701575.
04/08/2019 Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes Obes Metab., 2019;21(7):15701575.
04/03/2019 Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode BW.
鈥淏ioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.鈥�
Diabetes Obes Metab., 2019;21(4):1066-1070.
03/27/2019 Comparaison des profils pharmacocin茅tiques et de pharmacodynamie de l鈥檌nsuline ultra rapide BioChaperone庐 Lispro avec les formulations Fiasp庐 et Novorapid庐 de l鈥檌nsuline asparte administr茅es par pompes 脿 insuline, Dr. Gr茅gory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
03/27/2019 Comparaison des profils pharmacocin茅tiques et de pharmacodynamie de l鈥檌nsuline ultra rapide BioChaperone庐 Lispro avec les formulations Fiasp庐 et Novorapid庐 de l鈥檌nsuline asparte administr茅es par pompes 脿 insuline, Dr. Gr茅gory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
03/26/2019 鈥淏ioChaperone Combo, une combinaison fixe d鈥檌nsuline lispro et d鈥檌nsuline glargine, am茅liore les profils de glyc茅mie postprandiale par rapport 脿 un premix d鈥檌nsuline lispro et les administrations s茅par茅es d鈥檌nsuline lispro et d鈥檌nsuline glargine dans une 茅tude de phase 1 chez des sujets diab茅tiques de type 2鈥� (Poster), Author Dr. Claire M茅gret, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France) Icon check
Join our mailing list. Subscribe